Addison’s disease associated with advanced HIV may explain the high mortality

Dr Joseph B. Sempa

2024-03-10

Table of Contents

[Baseline table 1](#_Toc160997559)

[Table 1 2](#_Toc160997560)

[Table 1.2 3](#_Toc160997561)

[Table 2: comparing Addisons status with other variables 3](#_Toc160997562)

[Table 2.2: Cause of moratlity 6](#_Toc160997563)

[cross-tabulation 6](#_Toc160997564)

[Dotplot 11](#_Toc160997565)

[Table 3: Bivariate table 13](#_Toc160997566)

[Table 3a: Deep dive on Addison’s disease patients 13](#_Toc160997567)

[Table 3b: Deep dive in mortality status among Addissons cases 15](#_Toc160997568)

[Table 4: Multivariate table mortality 21](#_Toc160997569)

[Table 5 univariate analysis for addisson’s disease 28](#_Toc160997570)

# Baseline table

**Baseline table**

| Variable | **N = 528** |
| --- | --- |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.0, 43.0) |
| **Gender, n(%)** |  |
| Female | 269 (50.9%) |
| Male | 256 (48.5%) |
| Unknown | 3 (0.6%) |
| **Ethnicity, n(%)** |  |
| Black African | 421 (79.7%) |
| Other | 105 (19.9%) |
| Unknown | 2 (0.4%) |
| **Duration of current illness, median (IQR) (days)** | 14.0 (12.0, 21.0) |
| **log10 viral load** | 10.7 (7.4, 12.3) |
| **Total CD4 count** | 33.0 (15.0, 61.0) |
| **Tuberculosis** | 445 (84.3%) |
| **Cryptococcus neoformans** | 30 (5.7%) |
| **Pneumonia** | 62 (11.7%) |
| **Staph aureus** | 1 (0.2%) |
| **Kaposis sarcoma** | 6 (1.1%) |
| **Cytomegalovirus** | 1 (0.2%) |
| **HSV** | 8 (1.5%) |
| **HepB** | 18 (3.4%) |
| **Candida** | 29 (5.5%) |
| **GE/c diff** | 18 (3.4%) |
| **Parvo B19** | 1 (0.2%) |
| **Syphilis** | 17 (3.2%) |
| **B menigitis** | 5 (0.9%) |
| **UTI / Leptospirosis** | 7 (1.3%) |
| **PCP** | 4 (0.8%) |
| **COVID-19** | 2 (0.4%) |
| **Neurocysticercosis** | 2 (0.4%) |

# Table 1

| Variable | **Female**, N = 269 | **Male**, N = 256 | **p-value** |
| --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 35.0 (31.0, 42.0) | 37.0 (32.0, 44.5) | 0.017 |
| **Ethnicity, n(%)** |  |  | 0.6 |
| Black African | 210 (78.1%) | 210 (82.0%) |  |
| Other | 58 (21.6%) | 45 (17.6%) |  |
| Unknown | 1 (0.4%) | 1 (0.4%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (11.5, 21.0) | 14.0 (12.8, 21.0) | 0.6 |
| **log10 viral load** | 10.4 (7.2, 12.2) | 10.7 (7.7, 12.5) | 0.8 |
| **Total CD4 count** | 33.0 (15.0, 58.0) | 32.5 (12.8, 64.0) | >0.9 |
| **Sodium** | 134.0 (131.0, 138.0) | 133.0 (129.0, 136.0) | <0.001 |
| **Potassium** | 3.9 (3.5, 4.4) | 4.2 (3.9, 4.7) | <0.001 |
| **Haemoglobin** | 8.3 (7.1, 9.6) | 9.3 (7.9, 10.9) | <0.001 |
| **White cell count** | 5.3 (3.5, 8.0) | 5.4 (3.8, 8.3) | 0.8 |
| **Lymphocyte count** | 0.9 (0.3, 2.4) | 0.8 (0.5, 1.4) | 0.8 |
| **Neutrophils** | 3.3 (1.5, 10.2) | 3.2 (1.3, 7.3) | 0.6 |
| **Addisons disease** | 14 (5.2%) | 12 (4.7%) | 0.8 |
| **Tuberculosis** | 221 (82.2%) | 222 (86.7%) | 0.2 |
| **Cryptococcus neoformans** | 12 (4.5%) | 18 (7.0%) | 0.2 |
| **Pneumonia** | 30 (11.2%) | 32 (12.5%) | 0.6 |
| **Staph aureus** | 0 (0.0%) | 1 (0.4%) | 0.5 |
| **Kaposis sarcoma** | 4 (1.5%) | 2 (0.8%) | 0.7 |
| **Cytomegalovirus** | 0 (0.0%) | 1 (0.4%) | 0.5 |
| **HSV** | 4 (1.5%) | 4 (1.6%) | >0.9 |
| **HepB** | 7 (2.6%) | 11 (4.3%) | 0.3 |
| **Candida** | 17 (6.3%) | 12 (4.7%) | 0.4 |
| **GE/c diff** | 11 (4.1%) | 7 (2.7%) | 0.4 |
| **Parvo B19** | 1 (0.4%) | 0 (0.0%) | >0.9 |
| **Syphilis** | 8 (3.0%) | 9 (3.5%) | 0.7 |
| **B menigitis** | 4 (1.5%) | 1 (0.4%) | 0.4 |
| **UTI / Leptospirosis** | 1 (0.4%) | 6 (2.3%) | 0.063 |
| **PCP** | 2 (0.7%) | 2 (0.8%) | >0.9 |
| **COVID-19** | 1 (0.4%) | 1 (0.4%) | >0.9 |
| **Neurocysticercosis** | 0 (0.0%) | 2 (0.8%) | 0.2 |

# Table 1.2

# Table 2: comparing Addisons status with other variables

| Variable | **Overall**, N = 26 | **yes**, N = 26 | **no**, N = 0 | **p-value** |
| --- | --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.5, 46.0) | 36.0 (31.5, 46.0) | NA (NA, NA) |  |
| **Gender, n(%)** |  |  |  | >0.9 |
| Female | 14 (53.8%) | 14 (53.8%) | 0 (NA%) |  |
| Male | 12 (46.2%) | 12 (46.2%) | 0 (NA%) |  |
| **Ethnicity, n(%)** |  |  |  | >0.9 |
| Black African | 23 (88.5%) | 23 (88.5%) | 0 (NA%) |  |
| Other | 3 (11.5%) | 3 (11.5%) | 0 (NA%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (14.0, 30.0) | 14.0 (14.0, 30.0) | NA (NA, NA) |  |
| **Random cortisol** | 313.0 (251.5, 379.5) | 313.0 (251.5, 379.5) | NA (NA, NA) |  |
| **Basal cortisol** | 300.0 (196.3, 363.5) | 300.0 (196.3, 363.5) | NA (NA, NA) |  |
| **Stimulated cortisol** | 391.0 (320.8, 441.0) | 391.0 (320.8, 441.0) | NA (NA, NA) |  |
| **ACTH** | 28.0 (22.1, 69.6) | 28.0 (22.1, 69.6) | NA (NA, NA) |  |
| **BP (systolic)** | 120.0 (106.5, 128.8) | 120.0 (106.5, 128.8) | NA (NA, NA) |  |
| **BP (diastolic)** | 72.0 (64.8, 80.0) | 72.0 (64.8, 80.0) | NA (NA, NA) |  |
| **Heart rate** | 86.5 (77.8, 108.0) | 86.5 (77.8, 108.0) | NA (NA, NA) |  |
| **Hypotension** | 1 (3.8%) | 1 (3.8%) | 0 (NA%) | >0.9 |
| **Weakness** | 21 (80.8%) | 21 (80.8%) | 0 (NA%) | >0.9 |
| **Tiredness** | 23 (88.5%) | 23 (88.5%) | 0 (NA%) | >0.9 |
| **Poor appetite** | 22 (84.6%) | 22 (84.6%) | 0 (NA%) | >0.9 |
| **Weight loss** | 21 (80.8%) | 21 (80.8%) | 0 (NA%) | >0.9 |
| **Increased pigmentation of the skin** | 9 (34.6%) | 9 (34.6%) | 0 (NA%) | >0.9 |
| **Nausea** | 16 (61.5%) | 16 (61.5%) | 0 (NA%) | >0.9 |
| **Vomiting** | 8 (30.8%) | 8 (30.8%) | 0 (NA%) | >0.9 |
| **Liking for salt** | 18 (69.2%) | 18 (69.2%) | 0 (NA%) | >0.9 |
| **Hypoglycaemia** | 0 (0.0%) | 0 (0.0%) | 0 (NA%) |  |
| **Loss of consciousness** | 0 (0.0%) | 0 (0.0%) | 0 (NA%) |  |
| **Diarrhoea** | 8 (30.8%) | 8 (30.8%) | 0 (NA%) | >0.9 |
| **Dizziness** | 13 (50.0%) | 13 (50.0%) | 0 (NA%) | >0.9 |
| **Shock** | 0 (0.0%) | 0 (0.0%) | 0 (NA%) |  |
| **Anorexia** | 8 (30.8%) | 8 (30.8%) | 0 (NA%) | >0.9 |
| **Loss of axillary and pubic hair, if female** |  |  |  | >0.9 |
| No | 11 (42.3%) | 11 (42.3%) | 0 (NA%) |  |
| Not applicable | 12 (46.2%) | 12 (46.2%) | 0 (NA%) |  |
| Yes | 3 (11.5%) | 3 (11.5%) | 0 (NA%) |  |
| **Any postural drop in blood pressure** | 2 (7.7%) | 2 (7.7%) | 0 (NA%) | >0.9 |
| **Presence of anaemia** | 13 (50.0%) | 13 (50.0%) | 0 (NA%) | >0.9 |
| **Viral load (log10 Copies/mL)** | 11.0 (10.7, 11.3) | 11.0 (10.7, 11.3) | NA (NA, NA) |  |
| **Total CD4 count** | 25.5 (13.3, 50.3) | 25.5 (13.3, 50.3) | NA (NA, NA) |  |
| **Sodium mmol/L** | 135.0 (133.0, 137.0) | 135.0 (133.0, 137.0) | NA (NA, NA) |  |
| **Potassium mmol/L** | 3.9 (3.3, 4.1) | 3.9 (3.3, 4.1) | NA (NA, NA) |  |
| **Haemoglobin g/dL** | 8.7 (7.6, 10.4) | 8.7 (7.6, 10.4) | NA (NA, NA) |  |
| **White cell count X109** | 4.7 (2.7, 9.8) | 4.7 (2.7, 9.8) | NA (NA, NA) |  |
| **Lymphocyte count X109** | 0.9 (0.5, 1.3) | 0.9 (0.5, 1.3) | NA (NA, NA) |  |
| **Neutrophils** | 1.0 (0.9, 1.5) | 1.0 (0.9, 1.5) | NA (NA, NA) |  |
| **3 followup\_patientstatus** |  |  |  | >0.9 |
| Alive | 9 (34.6%) | 9 (34.6%) | 0 (NA%) |  |
| Deceased –> EXIT form | 3 (11.5%) | 3 (11.5%) | 0 (NA%) |  |
| NA | 14 (53.8%) | 14 (53.8%) | 0 (NA%) |  |
| **6 followup\_patientstatus** |  |  |  | >0.9 |
| Alive | 8 (30.8%) | 8 (30.8%) | 0 (NA%) |  |
| Deceased –> EXIT form | 5 (19.2%) | 5 (19.2%) | 0 (NA%) |  |
| NA | 13 (50.0%) | 13 (50.0%) | 0 (NA%) |  |
| **12 followup\_patientstatus** |  |  |  | >0.9 |
| Alive | 11 (42.3%) | 11 (42.3%) | 0 (NA%) |  |
| Deceased –> EXIT form | 5 (19.2%) | 5 (19.2%) | 0 (NA%) |  |
| NA | 10 (38.5%) | 10 (38.5%) | 0 (NA%) |  |




# Table 2.2: Cause of moratlity

## cross-tabulation

| Variable | **PAI**, N = 20 | **SAI**, N = 6 | **p-value** |
| --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.0, 42.3) | 43.0 (35.3, 51.5) | 0.3 |
| **Gender, n(%)** |  |  | 0.7 |
| Female | 10 (50.0%) | 4 (66.7%) |  |
| Male | 10 (50.0%) | 2 (33.3%) |  |
| **Ethnicity, n(%)** |  |  | >0.9 |
| Black African | 18 (90.0%) | 5 (83.3%) |  |
| Other | 2 (10.0%) | 1 (16.7%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (10.8, 15.8) | 30.0 (30.0, 30.0) | 0.013 |
| **Random cortisol** | 334.5 (254.5, 376.5) | 272.5 (237.5, 365.3) | 0.7 |
| **Basal cortisol** | 300.0 (190.3, 338.0) | 289.0 (213.8, 433.3) | 0.7 |
| **Stimulated cortisol** | 410.5 (339.3, 439.0) | 357.0 (197.8, 448.8) | 0.6 |
| **ACTH** | 42.4 (25.2, 76.0) | 9.5 (7.3, 12.7) | <0.001 |
| **BP (systolic)** | 120.0 (109.5, 128.5) | 115.0 (102.0, 125.8) | 0.6 |
| **BP (diastolic)** | 71.0 (68.3, 80.0) | 73.0 (61.0, 78.3) | 0.8 |
| **Heart rate** | 91.0 (76.8, 110.3) | 85.0 (82.5, 86.8) | 0.8 |
| **Hypotension** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Weakness** | 15 (75.0%) | 6 (100.0%) | 0.3 |
| **Tiredness** | 17 (85.0%) | 6 (100.0%) | >0.9 |
| **Poor appetite** | 18 (90.0%) | 4 (66.7%) | 0.2 |
| **Weight loss** | 18 (90.0%) | 3 (50.0%) | 0.062 |
| **Increased pigmentation of the skin** | 7 (35.0%) | 2 (33.3%) | >0.9 |
| **Nausea** | 11 (55.0%) | 5 (83.3%) | 0.4 |
| **Vomiting** | 6 (30.0%) | 2 (33.3%) | >0.9 |
| **Liking for salt** | 13 (65.0%) | 5 (83.3%) | 0.6 |
| **Hypoglycaemia** | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 5 (25.0%) | 3 (50.0%) | 0.3 |
| **Dizziness** | 10 (50.0%) | 3 (50.0%) | >0.9 |
| **Shock** | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 7 (35.0%) | 1 (16.7%) | 0.6 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.7 |
| No | 8 (40.0%) | 3 (50.0%) |  |
| Not applicable | 10 (50.0%) | 2 (33.3%) |  |
| Yes | 2 (10.0%) | 1 (16.7%) |  |
| **Any postural drop in blood pressure** | 1 (5.0%) | 1 (16.7%) | 0.4 |
| **Presence of anaemia** | 11 (55.0%) | 2 (33.3%) | 0.6 |
| **Presence of an opportunistic infection** |  |  |  |
| Yes | 20 (100.0%) | 6 (100.0%) |  |
| **Viral load (log10 Copies/mL)** | 11.0 (10.7, 11.3) | NA (NA, NA) |  |
| **CD4 count** | 25.5 (13.8, 50.5) | 32.0 (9.8, 49.0) | >0.9 |
| **Sodium mmol/L** | 134.5 (131.8, 137.0) | 136.0 (135.3, 138.3) | 0.2 |
| **Potassium mmol/L** | 3.8 (3.3, 4.1) | 3.9 (3.4, 4.1) | 0.9 |
| **Haemoglobin g/dL** | 8.5 (7.7, 10.3) | 8.7 (6.7, 10.5) | >0.9 |
| **White cell count X109** | 4.5 (2.5, 7.6) | 5.2 (4.1, 11.2) | 0.3 |
| **Lymphocyte count X109** | 1.3 (1.0, 17.5) | 0.5 (0.4, 0.8) | 0.2 |
| **Neutrophils** | 0.7 (0.6, 0.8) | 1.5 (1.3, 1.6) | 0.2 |
| **3 followup\_patientstatus** |  |  | 0.7 |
| Alive | 6 (30.0%) | 3 (50.0%) |  |
| Deceased –> EXIT form | 3 (15.0%) | 0 (0.0%) |  |
| NA | 11 (55.0%) | 3 (50.0%) |  |
| **6 followup\_patientstatus** |  |  | >0.9 |
| Alive | 6 (30.0%) | 2 (33.3%) |  |
| Deceased –> EXIT form | 4 (20.0%) | 1 (16.7%) |  |
| NA | 10 (50.0%) | 3 (50.0%) |  |
| **12 followup\_patientstatus** |  |  | 0.5 |
| Alive | 7 (35.0%) | 4 (66.7%) |  |
| Deceased –> EXIT form | 4 (20.0%) | 1 (16.7%) |  |
| NA | 9 (45.0%) | 1 (16.7%) |  |
| **Tuberculosis** | 15 (75.0%) | 5 (83.3%) | >0.9 |
| **Cryptococcus neoformans** | 9 (45.0%) | 1 (16.7%) | 0.4 |
| **Pneumonia** | 2 (10.0%) | 1 (16.7%) | >0.9 |
| **Staph aureus** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Cytomegalovirus** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HSV** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HepB** | 1 (5.0%) | 1 (16.7%) | 0.4 |
| **Candida** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Syphilis** | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  |

| Variable | **AI**, N = 26 | **No-AI**, N = 502 | **p-value** |
| --- | --- | --- | --- |
| **Age at enrolment, median (IQR) (years)** | 36 (32, 46) | 36 (31, 43) | 0.5 |
| **Gender, n(%)** |  |  | 0.9 |
| Female | 14 (53.8%) | 255 (50.8%) |  |
| Male | 12 (46.2%) | 244 (48.6%) |  |
| Unknown | 0 (0.0%) | 3 (0.6%) |  |
| **Ethnicity, n(%)** |  |  | 0.4 |
| Black African | 23 (88.5%) | 398 (79.3%) |  |
| Other | 3 (11.5%) | 102 (20.3%) |  |
| Unknown | 0 (0.0%) | 2 (0.4%) |  |
| **Duration of current illness, median (IQR) (days)** | 14 (14, 30) | 14 (12, 21) | 0.6 |
| **Random cortisol** | 313 (252, 380) | 477 (373, 577) | <0.001 |
| **Basal cortisol** | 300 (196, 364) | 466 (356, 572) | <0.001 |
| **Stimulated cortisol** | 391 (321, 441) | 722 (633, 854) | <0.001 |
| **ACTH** | 28 (22, 70) | 32 (20, 48) | 0.6 |
| **BP (systolic)** | 120 (107, 129) | 111 (102, 125) | 0.2 |
| **BP (diastolic)** | 72 (65, 80) | 70 (60, 79) | 0.083 |
| **Heart rate** | 87 (78, 108) | 91 (79, 109) | 0.7 |
| **Hypotension** | 1 (3.8%) | 40 (8.0%) | 0.7 |
| **Weakness** | 21 (80.8%) | 403 (80.3%) | >0.9 |
| **Tiredness** | 23 (88.5%) | 404 (80.5%) | 0.4 |
| **Poor appetite** | 22 (84.6%) | 357 (71.1%) | 0.14 |
| **Weight loss** | 21 (80.8%) | 414 (82.5%) | 0.8 |
| **Increased pigmentation of the skin** | 9 (34.6%) | 232 (46.2%) | 0.2 |
| **Nausea** | 16 (61.5%) | 249 (49.6%) | 0.2 |
| **Vomiting** | 8 (30.8%) | 133 (26.5%) | 0.6 |
| **Liking for salt** | 18 (69.2%) | 256 (51.0%) | 0.070 |
| **Hypoglycaemia** | 0 (0.0%) | 11 (2.2%) | >0.9 |
| **Loss of consciousness** | 0 (0.0%) | 7 (1.4%) | >0.9 |
| **Diarrhoea** | 8 (30.8%) | 205 (40.8%) | 0.3 |
| **Dizziness** | 13 (50.0%) | 222 (44.2%) | 0.6 |
| **Shock** | 0 (0.0%) | 5 (1.0%) | >0.9 |
| **Anorexia** | 8 (30.8%) | 220 (43.8%) | 0.2 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.8 |
| No | 11 (42.3%) | 191 (38.0%) |  |
| Not applicable | 12 (46.2%) | 222 (44.2%) |  |
| Yes | 3 (11.5%) | 89 (17.7%) |  |
| **Any postural drop in blood pressure** | 2 (7.7%) | 16 (3.2%) | 0.2 |
| **Presence of anaemia** | 13 (50.0%) | 273 (54.4%) | 0.7 |
| **Viral load (log10 Copies/mL)** | 11.0 (10.7, 11.3) | 10.7 (7.3, 12.3) | 0.8 |
| **CD4 count** | 26 (13, 50) | 34 (15, 61) | 0.4 |
| **Sodium mmol/L** | 135.0 (133.0, 137.0) | 134.0 (130.0, 137.0) | 0.063 |
| **Potassium mmol/L** | 3.85 (3.30, 4.15) | 4.10 (3.70, 4.60) | 0.039 |
| **Haemoglobin g/dL** | 8.65 (7.62, 10.37) | 8.70 (7.40, 10.33) | 0.9 |
| **White cell count X109** | 4.7 (2.7, 9.8) | 5.4 (3.7, 8.1) | 0.5 |
| **Lymphocyte count X109** | 0.9 (0.5, 1.3) | 0.8 (0.4, 1.8) | 0.7 |
| **Neutrophils** | 1 (1, 2) | 4 (2, 9) | 0.012 |
| **3 followup\_patientstatus** |  |  | 0.12 |
| Alive | 9 (34.6%) | 124 (24.8%) |  |
| Deceased –> EXIT form | 3 (11.5%) | 26 (5.2%) |  |
| NA | 14 (53.8%) | 351 (70.1%) |  |
| **6 followup\_patientstatus** |  |  | 0.045 |
| Alive | 8 (30.8%) | 134 (26.7%) |  |
| Deceased –> EXIT form | 5 (19.2%) | 34 (6.8%) |  |
| NA | 13 (50.0%) | 333 (66.5%) |  |
| **12 followup\_patientstatus** |  |  | 0.065 |
| Alive | 11 (42.3%) | 168 (33.5%) |  |
| Deceased –> EXIT form | 5 (19.2%) | 44 (8.8%) |  |
| NA | 10 (38.5%) | 289 (57.7%) |  |
| **Tuberculosis** | 20 (76.9%) | 425 (84.7%) | 0.3 |
| **Cryptococcus neoformans** | 10 (38.5%) | 20 (4.0%) | <0.001 |
| **Pneumonia** | 3 (11.5%) | 59 (11.8%) | >0.9 |
| **Staph aureus** | 1 (3.8%) | 0 (0.0%) | 0.049 |
| **Kaposis sarcoma** | 1 (3.8%) | 5 (1.0%) | 0.3 |
| **Cytomegalovirus** | 1 (3.8%) | 0 (0.0%) | 0.049 |
| **HSV** | 1 (3.8%) | 7 (1.4%) | 0.3 |
| **HepB** | 2 (7.7%) | 16 (3.2%) | 0.2 |
| **Candida** | 1 (3.8%) | 28 (5.6%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 18 (3.6%) | >0.9 |
| **Parvo B19** | 1 (3.8%) | 0 (0.0%) | 0.049 |
| **Syphilis** | 0 (0.0%) | 17 (3.4%) | >0.9 |
| **B menigitis** | 0 (0.0%) | 5 (1.0%) | >0.9 |
| **UTI / Leptospirosis** | 0 (0.0%) | 7 (1.4%) | >0.9 |
| **PCP** | 0 (0.0%) | 4 (0.8%) | >0.9 |
| **COVID-19** | 0 (0.0%) | 2 (0.4%) | >0.9 |
| **Neurocysticercosis** | 0 (0.0%) | 2 (0.4%) | >0.9 |

# Dotplot

png 2 png 2 png 2

# Table 3: Bivariate table

# Table 3a: Deep dive on Addison’s disease patients

| Variable | **1**, N = 6 | **0**, N = 58 | **p-value** |
| --- | --- | --- | --- |
| **Age at enrolment median (IQR) (years)** | 41 (33, 46) | 39 (33, 45) | 0.7 |
| **Gender, n(%)** |  |  | >0.9 |
| Female | 3 (50.0%) | 32 (55.2%) |  |
| Male | 3 (50.0%) | 26 (44.8%) |  |
| Unknown | 0 (0.0%) | 0 (0.0%) |  |
| **Ethnicity, n(%)** |  |  | 0.2 |
| Black African | 4 (66.7%) | 50 (86.2%) |  |
| Other | 2 (33.3%) | 8 (13.8%) |  |
| **Duration of current illness, median (IQR) (days)** | NA (NA, NA) | NA (NA, NA) |  |
| **Random cortisol** | 307 (262, 336) | 481 (369, 616) | 0.003 |
| **Basal cortisol** | 308 (246, 365) | 500 (433, 636) | <0.001 |
| **Stimulated cortisol** | 375 (338, 424) | 795 (662, 890) | <0.001 |
| **ACTH** | 42 (26, 78) | 40 (25, 59) | 0.8 |
| **BP (systolic)** | 128 (122, 130) | 110 (102, 120) | 0.051 |
| **BP (diastolic)** | 74 (65, 78) | 70 (66, 80) | >0.9 |
| **Heart rate** | 87 (72, 98) | 93 (82, 109) | 0.2 |
| **Hypotension** | 0 (0.0%) | 7 (12.1%) | >0.9 |
| **Weakness** | 4 (66.7%) | 52 (89.7%) | 0.2 |
| **Tiredness** | 6 (100.0%) | 50 (86.2%) | >0.9 |
| **Poor appetite** | 6 (100.0%) | 49 (84.5%) | 0.6 |
| **Weight loss** | 4 (66.7%) | 50 (86.2%) | 0.2 |
| **Increased pigmentation of the skin** | 2 (33.3%) | 35 (60.3%) | 0.2 |
| **Nausea** | 5 (83.3%) | 36 (62.1%) | 0.4 |
| **Vomiting** | 2 (33.3%) | 15 (25.9%) | 0.7 |
| **Liking for salt** | 4 (66.7%) | 38 (65.5%) | >0.9 |
| **Hypoglycaemia** | 0 (0.0%) | 2 (3.4%) | >0.9 |
| **Loss of consciousness** | 0 (0.0%) | 2 (3.4%) | >0.9 |
| **Diarrhoea** | 1 (16.7%) | 32 (55.2%) | 0.10 |
| **Dizziness** | 3 (50.0%) | 33 (56.9%) | >0.9 |
| **Shock** | 0 (0.0%) | 2 (3.4%) | >0.9 |
| **Anorexia** | 2 (33.3%) | 34 (58.6%) | 0.4 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.8 |
| No | 2 (33.3%) | 16 (27.6%) |  |
| Not applicable | 3 (50.0%) | 23 (39.7%) |  |
| Yes | 1 (16.7%) | 19 (32.8%) |  |
| **Any postural drop in blood pressure** | 0 (0.0%) | 4 (6.9%) | >0.9 |
| **Presence of anaemia** | 3 (50.0%) | 36 (62.1%) | 0.7 |
| **Tuberculosis** | 5 (83.3%) | 47 (81.0%) | >0.9 |
| **Cryptococcus neoformans** | 3 (50.0%) | 3 (5.2%) | 0.009 |
| **Pneumonia** | 0 (0.0%) | 7 (12.1%) | >0.9 |
| **Staph aureus** | 0 (0.0%) | 0 (0.0%) |  |
| **Kaposis sarcoma** | 0 (0.0%) | 0 (0.0%) |  |
| **Cytomegalovirus** | 0 (0.0%) | 0 (0.0%) |  |
| **HSV** | 0 (0.0%) | 1 (1.7%) | >0.9 |
| **HepB** | 1 (16.7%) | 0 (0.0%) | 0.094 |
| **Candida** | 0 (0.0%) | 4 (6.9%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 0 (0.0%) |  |
| **Syphilis** | 0 (0.0%) | 2 (3.4%) | >0.9 |
| **B menigitis** | 0 (0.0%) | 1 (1.7%) | >0.9 |
| **UTI / Leptospirosis** | 0 (0.0%) | 1 (1.7%) | >0.9 |
| **PCP** | 0 (0.0%) | 2 (3.4%) | >0.9 |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  |
| **Viral load (log10 Copies/mL)** | NA (NA, NA) | 12.00 (10.29, 13.14) |  |
| **Total CD4 count** | 30 (16, 45) | 26 (13, 54) | 0.7 |
| **Sodium mmol/L** | 136.5 (133.3, 139.0) | 133.0 (127.5, 136.0) | 0.2 |
| **Potassium mmol/L** | 3.70 (3.37, 3.88) | 3.90 (3.60, 4.60) | 0.092 |
| **Haemoglobin g/dL** | 9.60 (8.25, 10.95) | 8.35 (7.05, 9.67) | 0.4 |
| **White cell count X109** | 8.3 (4.3, 27.5) | 5.0 (3.4, 7.4) | 0.2 |
| **Lymphocyte count X109** | NA (NA, NA) | 0.80 (0.40, 0.99) |  |

# Table 3b: Deep dive in mortality status among Addissons cases

| Variable | **yes**, N = 6 | **no**, N = 20 | **p-value** |
| --- | --- | --- | --- |
| **Age at enrolment median (IQR) (years)** | 41 (33, 46) | 36 (33, 44) | 0.7 |
| **Gender, n(%)** |  |  | >0.9 |
| Female | 3 (50.0%) | 11 (55.0%) |  |
| Male | 3 (50.0%) | 9 (45.0%) |  |
| Unknown | 0 (0.0%) | 0 (0.0%) |  |
| **Ethnicity, n(%)** |  |  | 0.12 |
| Black African | 4 (66.7%) | 19 (95.0%) |  |
| Other | 2 (33.3%) | 1 (5.0%) |  |
| **Duration of current illness, median (IQR) (days)** | NA (NA, NA) | NA (NA, NA) |  |
| **Random cortisol** | 307 (262, 336) | 316 (236, 382) | >0.9 |
| **Basal cortisol** | 308 (246, 365) | 292 (184, 355) | 0.6 |
| **Stimulated cortisol** | 375 (338, 424) | 399 (313, 465) | 0.7 |
| **ACTH** | 42 (26, 78) | 26 (20, 66) | 0.6 |
| **BP (systolic)** | 128 (122, 130) | 120 (103, 128) | 0.2 |
| **BP (diastolic)** | 74 (65, 78) | 72 (68, 81) | 0.7 |
| **Heart rate** | 87 (72, 98) | 87 (79, 114) | 0.4 |
| **Hypotension** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **Weakness** | 4 (66.7%) | 17 (85.0%) | 0.6 |
| **Tiredness** | 6 (100.0%) | 17 (85.0%) | >0.9 |
| **Poor appetite** | 6 (100.0%) | 16 (80.0%) | 0.5 |
| **Weight loss** | 4 (66.7%) | 17 (85.0%) | 0.6 |
| **Increased pigmentation of the skin** | 2 (33.3%) | 7 (35.0%) | >0.9 |
| **Nausea** | 5 (83.3%) | 11 (55.0%) | 0.4 |
| **Vomiting** | 2 (33.3%) | 6 (30.0%) | >0.9 |
| **Liking for salt** | 4 (66.7%) | 14 (70.0%) | >0.9 |
| **Hypoglycaemia** | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 1 (16.7%) | 7 (35.0%) | 0.6 |
| **Dizziness** | 3 (50.0%) | 10 (50.0%) | >0.9 |
| **Shock** | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 2 (33.3%) | 6 (30.0%) | >0.9 |
| **Loss of axillary and pubic hair, if female** |  |  | >0.9 |
| No | 2 (33.3%) | 9 (45.0%) |  |
| Not applicable | 3 (50.0%) | 9 (45.0%) |  |
| Yes | 1 (16.7%) | 2 (10.0%) |  |
| **Any postural drop in blood pressure** | 0 (0.0%) | 2 (10.0%) | >0.9 |
| **Presence of anaemia** | 3 (50.0%) | 10 (50.0%) | >0.9 |
| **Tuberculosis** | 5 (83.3%) | 15 (75.0%) | >0.9 |
| **Cryptococcus neoformans** | 3 (50.0%) | 7 (35.0%) | 0.6 |
| **Pneumonia** | 0 (0.0%) | 3 (15.0%) | >0.9 |
| **Staph aureus** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **Kaposis sarcoma** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **Cytomegalovirus** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **HSV** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **HepB** | 1 (16.7%) | 1 (5.0%) | 0.4 |
| **Candida** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 1 (5.0%) | >0.9 |
| **Syphilis** | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  |
| **Viral load (log10 Copies/mL)** |  |  | >0.9 |
| 10.4579184937828 | 0 (NA%) | 1 (50.0%) |  |
| 11.60516730587 | 0 (NA%) | 1 (50.0%) |  |
| **Total CD4 count** | 30 (16, 45) | 26 (10, 53) | 0.8 |
| **Sodium mmol/L** | 136.5 (133.3, 139.0) | 135.0 (132.8, 136.3) | 0.6 |
| **Potassium mmol/L** | 3.70 (3.37, 3.88) | 3.95 (3.27, 4.58) | 0.4 |
| **Haemoglobin g/dL** | 9.60 (8.25, 10.95) | 8.50 (7.57, 10.22) | 0.4 |
| **White cell count X109** | 8 (4, 27) | 4 (3, 6) | 0.2 |
| **Lymphocyte count X109** |  |  | >0.9 |
| 0.360000014305115 | 0 (NA%) | 1 (16.7%) |  |
| 0.490000009536743 | 0 (NA%) | 1 (16.7%) |  |
| 0.600000023841858 | 0 (NA%) | 1 (16.7%) |  |
| 1.10000002384186 | 0 (NA%) | 1 (16.7%) |  |
| 1.30999994277954 | 0 (NA%) | 1 (16.7%) |  |
| 33.5999984741211 | 0 (NA%) | 1 (16.7%) |  |
| **Addisons disease** |  |  | >0.9 |
| 0 | 0 (0.0%) | 0 (0.0%) |  |
| 1 | 6 (100.0%) | 20 (100.0%) |  |

| **Characteristic** | **N** | **HR** | **95% CI** | **p-value** |
| --- | --- | --- | --- | --- |
| Age\_at\_enrolment | 527 | 1.02 | 0.99, 1.04 | 0.2 |
| Gender | 528 |  |  |  |
| Female |  | — | — |  |
| Male |  | 0.86 | 0.53, 1.41 | 0.6 |
| Unknown |  | 0.00 | 0.00, Inf | >0.9 |
| Ethnicity | 528 |  |  |  |
| Black African |  | — | — |  |
| Other |  | 0.73 | 0.37, 1.43 | 0.4 |
| Unknown |  | 0.00 | 0.00, Inf | >0.9 |
| Random\_cortisol | 425 | 1.00 | 1.00, 1.00 | 0.5 |
| Basal\_cortisol | 148 | 1.00 | 1.00, 1.00 | 0.2 |
| Stimulated\_cortisol | 145 | 1.00 | 1.00, 1.00 | >0.9 |
| ACTH | 425 | 1.01 | 1.00, 1.01 | <0.001 |
| BP\_systolic | 519 | 0.99 | 0.98, 1.01 | 0.3 |
| BP\_diastolic | 519 | 1.01 | 1.00, 1.03 | 0.12 |
| Heart\_rate | 518 | 1.00 | 0.99, 1.02 | 0.4 |
| Hypotension | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.48 | 0.68, 3.25 | 0.3 |
| Weakness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.74 | 0.83, 3.65 | 0.14 |
| Tiredness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.68 | 0.80, 3.53 | 0.2 |
| Poor\_appetite | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.49 | 1.23, 5.04 | 0.011 |
| Weight\_loss | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.15 | 0.58, 2.25 | 0.7 |
| Increased\_pigmentation\_of\_the\_skin | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.66 | 1.01, 2.73 | 0.045 |
| Nausea | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.83 | 1.10, 3.04 | 0.021 |
| Vomiting | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.00 | 0.58, 1.75 | >0.9 |
| Liking\_for\_salt | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.83 | 1.09, 3.07 | 0.021 |
| Hypoglycaemia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.50 | 0.37, 6.13 | 0.6 |
| Loss\_of\_consciousness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.60 | 0.64, 10.6 | 0.2 |
| Diarrhoea | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.60 | 0.98, 2.62 | 0.059 |
| Dizziness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.65 | 1.01, 2.70 | 0.047 |
| Shock | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 3.82 | 0.93, 15.6 | 0.062 |
| Anorexia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.73 | 1.06, 2.84 | 0.030 |
| Loss\_of\_axillary\_and\_pubic\_hair | 528 |  |  |  |
| No |  | — | — |  |
| Not applicable |  | 1.25 | 0.68, 2.28 | 0.5 |
| Yes |  | 2.58 | 1.36, 4.88 | 0.004 |
| Any\_postural\_drop\_in\_blood\_pressure | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.97 | 0.72, 5.42 | 0.2 |
| Presence\_of\_anaemia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.33 | 0.81, 2.20 | 0.3 |
| Tuberculosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.79 | 0.42, 1.48 | 0.5 |
| Cryptococcus neoformans | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.80 | 0.78, 4.17 | 0.2 |
| Pneumonia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.93 | 0.42, 2.04 | 0.9 |
| Staph aureus | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Kaposis sarcoma | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Cytomegalovirus | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| HSV | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.99 | 0.14, 7.10 | >0.9 |
| HepB | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.43 | 0.06, 3.11 | 0.4 |
| Candida | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.18 | 0.43, 3.24 | 0.7 |
| GE/c diff | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Parvo B19 | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Syphilis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.92 | 0.23, 3.78 | >0.9 |
| B menigitis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.70 | 0.24, 12.3 | 0.6 |
| UTI / Leptospirosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.18 | 0.16, 8.51 | 0.9 |
| PCP | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 5.68 | 1.39, 23.2 | 0.016 |
| COVID-19 | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Neurocysticercosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 | 0.00, Inf | >0.9 |
| Viral\_load | 115 | 1.24 | 1.04, 1.49 | 0.019 |
| CD4\_count | 522 | 0.99 | 0.98, 1.00 | 0.2 |
| Sodium | 498 | 1.00 | 0.98, 1.02 | >0.9 |
| Potassium | 496 | 0.98 | 0.94, 1.04 | 0.5 |
| Haemoglobin | 522 | 0.98 | 0.88, 1.10 | 0.8 |
| White\_cell\_count | 518 | 1.00 | 1.00, 1.00 | >0.9 |
| Lymphocyte\_count | 120 | 0.92 | 0.81, 1.06 | 0.3 |
| Addisons\_disease | 528 |  |  |  |
| 0 |  | — | — |  |
| 1 |  | 2.19 | 0.94, 5.07 | 0.068 |

# Table 4: Multivariate table mortality

The rule of thumb for MV models such as this on you need at least 10 people per outcome. We have 53 people with the outcome, yet we have 6 variables adjusted for in the model (using stepwise regression). I suggest we remove one variable from the list that you think may not be biologically contributing to the relationship. (see accompanying file)

# Table 5 Univariate analysis for Addisson’s disease

| **Characteristic** | **N** | **OR** | **95% CI** | **p-value** |
| --- | --- | --- | --- | --- |
| Age\_at\_enrolment | 527 | 0.98 | 0.94, 1.03 | 0.4 |
| Gender | 528 |  |  |  |
| Female |  | — | — |  |
| Male |  | 1.12 | 0.51, 2.50 | 0.8 |
| Unknown |  | 316,115 | 0.00, NA | >0.9 |
| Ethnicity | 528 | 2.01 | 0.70, 8.50 | 0.3 |
| Duration\_of\_current\_illness | 494 | 1.03 | 0.97, 1.30 | 0.7 |
| Random\_cortisol | 425 | 1.11 | 1.07, 1.16 | <0.001 |
| Basal cortisol | 148 | 1.10 | 1.05, 1.15 | <0.001 |
| Stimulated cortisol | 145 | 44,568,772 | 0.00, Inf | >0.9 |
| ACTH | 425 | 0.93 | 0.86, 1.00 | 0.033 |
| BP (systolic) | 519 | 0.99 | 0.97, 1.02 | 0.5 |
| BP (diastolic) | 519 | 0.98 | 0.95, 1.01 | 0.2 |
| Any postural drop in blood pressure | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.40 | 0.10, 2.59 | 0.2 |
| Heart rate | 518 | 1.00 | 0.99, 1.02 | 0.7 |
| Hypotension | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2.16 | 0.44, 39.2 | 0.5 |
| Weakness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.97 | 0.32, 2.45 | >0.9 |
| Tiredness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.54 | 0.13, 1.58 | 0.3 |
| Poor appetite | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.45 | 0.13, 1.19 | 0.15 |
| Weight loss | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.12 | 0.37, 2.84 | 0.8 |
| Increased pigmentation of the skin | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.62 | 0.73, 3.87 | 0.3 |
| Nausea | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.62 | 0.26, 1.36 | 0.2 |
| Vomiting | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.81 | 0.36, 2.02 | 0.6 |
| Liking for salt | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.46 | 0.19, 1.05 | 0.076 |
| Hypoglycaemia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2,252,882 | 0.00, NA | >0.9 |
| Loss of consciousness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 822,092 | 0.00, NA | >0.9 |
| Diarrhoea | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.55 | 0.68, 3.85 | 0.3 |
| Dizziness | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.79 | 0.36, 1.76 | 0.6 |
| Shock | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 818,783 | 0.00, NA | >0.9 |
| Anorexia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.76 | 0.77, 4.35 | 0.2 |
| Loss of axillary and pubic hair, if female | 528 |  |  |  |
| No |  | — | — |  |
| Not applicable |  | 1.07 | 0.45, 2.48 | 0.9 |
| Yes |  | 1.71 | 0.52, 7.69 | 0.4 |
| Presence of anaemia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.19 | 0.54, 2.65 | 0.7 |
| Viral load (log10 Copies/mL) | 115 | 0.89 | 0.53, 1.33 | 0.6 |
| CD4 count | 522 | 1.03 | 0.96, 1.11 | 0.4 |
| Sodium mmol/L | 498 | 0.83 | 0.66, 1.05 | 0.13 |
| Potassium mmol/L | 496 | 1.04 | 0.88, 1.85 | 0.8 |
| Haemoglobin g/dL | 522 | 1.00 | 0.99, NA | 0.9 |
| White cell count X109 | 518 | 0.99 | 0.98, 1.02 | 0.4 |
| Lymphocyte count X109 | 120 | 1.01 | 0.96, NA | >0.9 |
| Neutrophils | 121 | 95.1 | 1.83, 87,823 | 0.094 |
| 3 followup\_patientstatus | 527 |  |  |  |
| Alive |  | — | — |  |
| Deceased –> EXIT form |  | 0.42 | 0.13, 1.85 | 0.2 |
| 6 followup\_patientstatus | 527 |  |  |  |
| Alive |  | — | — |  |
| Deceased –> EXIT form |  | 0.29 | 0.11, 0.93 | 0.021 |
| NA |  | 0.22 | 0.03, 4.25 | 0.2 |
| 12 followup\_patientstatus | 527 |  |  |  |
| Alive |  | — | — |  |
| Deceased –> EXIT form |  | 0.40 | 0.15, 1.24 | 0.078 |
| NA |  | 0.63 | 0.12, 11.7 | 0.7 |
| Tuberculosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.66 | 0.59, 4.03 | 0.3 |
| Cryptococcus neoformans | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.07 | 0.03, 0.17 | <0.001 |
| Pneumonia | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.02 | 0.34, 4.40 | >0.9 |
| Staph aureus | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Kaposis sarcoma | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.25 | 0.04, 4.91 | 0.2 |
| Cytomegalovirus | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| HSV | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.35 | 0.06, 6.74 | 0.3 |
| HepB | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.40 | 0.10, 2.59 | 0.2 |
| Candida | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 1.48 | 0.30, 26.9 | 0.7 |
| GE/c diff | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2,285,465 | 0.00, NA | >0.9 |
| Parvo B19 | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 0.00 |  | >0.9 |
| Syphilis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 2,280,753 | 0.00, NA | >0.9 |
| B menigitis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 818,783 | 0.00, NA | >0.9 |
| UTI / Leptospirosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 822,092 | 0.00, NA | >0.9 |
| PCP | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 817,139 | 0.00, NA | >0.9 |
| COVID-19 | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 299,406 | 0.00, NA | >0.9 |
| Neurocysticercosis | 528 |  |  |  |
| FALSE |  | — | — |  |
| TRUE |  | 299,406 | 0.00, NA | >0.9 |